Wolfgang Nachbauer

Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (<scp>MOXIe</scp> Study)

David R. Lynch, Melanie Chin, Martin B. Delatycki et al. · Annals of Neurology · 2020 · 296 citations · Full text

Medicine, Neurology, Pharmacology +17

AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders

Vincenzo Salpietro, Christine L. Dixon, Hui Guo et al. · Nature Communications · 2019 · 249 citations · Full text

Life Sciences, Genetics, Neuroscience +17

Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data

Kathrin Reetz, Imis Dogan, Ana Sofia Costa et al. · The Lancet Neurology · 2015 · 211 citations

Life Sciences, Neurology, Neuroscience +11

Consensus Paper: Management of Degenerative Cerebellar Disorders

Winfried Ilg, Amy J. Bastian, Sylvia Boesch et al. · The Cerebellum · 2013 · 210 citations

Life Sciences, Neurology, Neuroscience +14

Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia

David R. Lynch, Jennifer Farmer, Lauren Hauser et al. · Annals of Clinical and Translational Neurology · 2018 · 166 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13